AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05358509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
Study NCT05358509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside
Description: Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
Study NCT05358509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Sulfate
Description: Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
Study NCT06331767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mSYNC
Description: mSYNC in an mHealth HIV prevention intervention to be initially delivered at point-of-care during a visit to the emergency department with continued on demand access to intervention app at home. Taking a behavioral medicine approach, mSYNC simulates hospital-based consultation \& liaison psychology service by intervening on interrelated health risk behaviors, mental health issues, and structural/treatment needs. The mHealth app includes modules with motivational interviewing for HIV/drug use risk behaviors, cognitive behavioral therapy for transdiagnostic psychological coping skills, referral system for needed hospital-based services (mental health/drug use treatment; HIV prevention; social services), and access to geolocated resources.
Study NCT06090669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: Imatinib at 100-400 mg PO QD based on arm assignment/dose level
Study NCT06090669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruSight Oncology
Description: Assay sequencing platform to identify pathogenic genetic mutations in DNA and RNA
Study NCT06362694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib + Trametinib
Description: Dabrafenib is an inhibitor of some mutated forms of BRAF kinases. Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib 623 and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumors.
Study NCT05371613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose
Study NCT05371613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idursulfase
Description: Intravenous repeating dose
Study NCT05603312 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-GAD Dose 1
Description: Bilateral infusion of AAV-GAD Dose 1
Study NCT05603312 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-GAD Dose 2
Description: Bilateral infusion of AAV-GAD Dose 2
Study NCT05603312 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Description: Sham infusion
Study NCT06481488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.
Study NCT04933656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one 24 hr cycle of meals at a 2000 kcal level
Description: 50g added sugar
Study NCT04933656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one 24 hr cycle of meals at a 2000 kcal level + one serving sugar sweetened beverage
Description: 90 grams added sugar
Study NCT04583787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi myocardial perfusion SPECT
Description: 82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
Study NCT06190730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voice-Assisted Remote Symptom Monitoring System (VARSMS)
Description: Utilizing an Alexa Skill activated via an Amazon Echo Dot device, this system will administer two patient-reported outcomes measures to subjects. This will not be used as basis for diagnosis, nor for any clinical intervention.
Study NCT06516952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral Tablet
Study NCT06516952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT05784753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART Camp
Description: Participants will meet with an in-person coach at the medical fitness center: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a 1-hour group-based exercise training and coaching).
Study NCT05784753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART Camp Connect
Description: Participants will meet with a virtual coach from the medical fitness center via videoconferencing: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a virtual 1-hour group-based exercise training and coaching session via videoconferencing).
Study NCT04979039 — intervention group
Intervention type: OTHER
Intervention: analgesia nociception index (ANI) monitoring
Description: The ANI monitor starts lying on the bed in the waiting area before entering the operating room, and the monitoring period should be at least 15 minutes. After entering the operating room, monitoring begins again and is maintained during the operation.
Study NCT06274749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Urolithin A
Description: Urolithin A (UA) is a widely available dietary supplement devoid of any known sided effects that is reported to improve mitochondrial function. The UA substance used in this investigation is regulated under Generally Recognized as Safe (GRAS) by the US FDA (GRN No. 000791) (https://www.fda.gov/media/120300/download) and is being advertised and sold as an oral supplement. The daily dose (1 gram) and duration (8 weeks) have already been tested in previous clinical trials.
Study NCT06274749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will consist of methylcellulose and will appear identical to the active supplement. The placebo will be provided by the manufacturer of Urolithin A.
Study NCT04583787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 82Rb-Chloride myocardial perfusion PET with CCTA
Description: stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
Study NCT04933656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one 24 hr cycle of meals at a 2000 kcal level + two servings sugar sweetened beverage
Description: 130 grams added sugar
Study NCT05322512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
Study NCT05006716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered
Study NCT05964504 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Specimen
Description: Blood will be drawn via venipuncture
Study NCT06481488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.
Study NCT06779474 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic ALPPS
Description: Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy
Study NCT06330064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration
Study NCT06477692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENI using IMRT with or without chemotherapy
Description: This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
Study NCT06477692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENI using IMRT with or without chemotherapy
Description: This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
Study NCT06477692 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: INRT
Description: INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
Study NCT06477692 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: ENI
Description: ENI using IMRT with or without chemotherapy
Study NCT04933656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one 24 hr cycle of meals at a 2000 kcal level + three serving sugar sweetened beverage
Description: 170 grams added sugar
Study NCT06508216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Patients in module 1 \& 2 will receive Datopotamab Deruxtecan (Dato-DXd) 6mg/kg every 21 days
Study NCT06508216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients in module 2 only will receive Durvalumab 1120mg every 21 days
Study NCT05723562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study NCT06580249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。
Study NCT06580249 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。
Study NCT05643196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLIFUS
Description: The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
Study NCT05643196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham PLIFUS
Description: Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
Study NCT05643196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
Study NCT04036331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brenner FIT Standard
Description: After referral, families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and physical activity specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, physical activity, and parenting. Specialized visits with the physical activity specialist or dietician are scheduled as pertinent issues arise. Clinic visits include individualized goal setting (for behaviors family/clinician have agreed to address), healthy eating and physical activity education, and behavioral counseling to implement changes at home.
Study NCT04036331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: By Design Essentials
Description: A dietitian provides each participant with a detailed program manual that describes the prescribed diet. The dietitian utilizes standard behavioral techniques to promote lifestyle behavior changes that enable participants to implement and maintain behaviors necessary to adhere to the dietary prescription. Participants also receive a standard exercise program designed to promote exercise energy expenditure of approximately 600 kilocalories\*/week. The exercise prescription includes resistance training for 2 days per week and aerobic training for 3 days per week, to meet a 600 kilocalories\*/week expenditure goal. Behaviorists meet with participants to provide individual and group-based counseling to learn the skills necessary to adopt the prescribed dietary pattern and exercise plans. Group sessions will be delivered consecutively over 6 months (20 total; 1.5 hours each).
Study NCT04036331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyad Plus
Description: This will include all components of the standard Brenner FIT program and By Design Essentials.~In addition, group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. Dyads will attend 6 meetings that will last approximately 1 hour each.
Study NCT05777993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Tablets
Study NCT05188170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
Study NCT06212063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cadet Health
Description: Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
Study NCT05457907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound device
Description: Low energy ultrasound therapy will be administered to the spleen
Study NCT05088746 — intervention group
Intervention type: PROCEDURE
Intervention: Non-surgical periodontal therapy
Description: NSPT will be performed following the principles of minimally invasive non-surgical therapy (MINST) described by Nibali et al. (Nibali et al., 2015, Nibali et al., 2019)
Study NCT06561386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT06561386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study NCT06561386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Specified dose on specified days
Study NCT06561386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT06561386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT06561386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT06561386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT06561386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT06561386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT06396260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Kurtosis Imaging (DKI)
Description: Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue
Study NCT06396260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting State Magnetoencephalography
Description: Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)
Study NCT06778382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oligometastasis Treatment
Description: Oligometastatic Radiotherapy Group: Patients will receive radiotherapy to lung lesions, with the lung metastases outlined as the Gross Tumor Volume (GTV). The prescribed dose will be based on a BED (Biologically Effective Dose) of 72-100 Gy, using either conventional split, macrodissected, or SBRT (Stereotactic Body Radiation Therapy) at the investigator's discretion. No systemic therapy will be administered.~Oligometastatic Radiofrequency Ablation Group: For lesions suitable for radiofrequency ablation, this will be performed in consultation with the Department of Interventional Medicine, considering patient and family preferences. Systemic therapy will not be given.~Oligometastatic Surgery Group: For lesions suitable for surgical resection, patients will undergo surgery after consultation with the Department of Surgery. No systemic therapy will be performed.
Study NCT06779448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of objective and subjective stress parameters caused by local anesthesia during treatments
Description: Patients were divided according to the randomization procedure. infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetic, an appropriate size rubber dam and metal clamp was placed i and pit and fissure sealant was applied. The stress parameters of the subjects were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
Study NCT06502132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education Group
Description: Patients whose surgery has been postponed will be educated by the researcher through a booklet regarding the waiting process. The education includes information such as anxiety management, pain management, and re-surgery planning. The booklet consists of 22 pages and a copy is given to each patient in this group. The education lasts between 15-20 minutes and the patients' questions are answered. It is applied in a single session.
Study NCT06502132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Touch Group
Description: Therapeutic touch application is applied as a single session and lasts approximately 20-25 minutes. The therapeutic touch that emerges from the artistic aspect of nursing is an energybased practice that does not involve physical contact. Therapeutic touch is a conscious and compassionate effort to direct the flow of one's universal life energy to healing by influencing this energy.
Study NCT06779448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of objective and subjective stress parameters caused by topical anesthesia during treatments
Description: Patients were divided i according to the randomization procedure. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds. Following the administration of anesthetic, an appropriate size rubber dam and metal clamp was placed i and pit and fissure sealant was applied. The stress parameters of the subjects were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
Study NCT06779448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of objective and subjective stress parameters caused by the application of rubber dam during treatments in the patient and dentist
Description: Patients were divided into 4 subgroups according to the randomization procedure: topical anesthesia and infiltrative anesthesia before the placement of the clamp and also cotton roll application other side of the arch. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds and infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetics, an appropriate size rubber dam and metal clamp was placed in the mandibular arch, and pit and fissure sealant was applied to the opposite arch. The stress parameters of the subjects and dentist were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.